prosthetic heart valves
Mechanical valve → lifelong warfarin; never DOAC. Bioprosthetic valve → no long-term anticoagulation unless another indication; after TAVI → ASA alone. Mechanical lasts but needs warfarin; tissue valves avoid warfarin but degenerate — so younger patients get mechanical, older patients tissue. Any prosthesis (including TAVI) → endocarditis prophylaxis before dental extractions. A rising gradient → compare with the baseline echo and find the cause (thrombosis, pannus, degeneration, mismatch, high flow, endocarditis); a mechanical valve with pulmonary oedema or shock → thrombosis until proven otherwise.
choice of prosthesis
| Mechanical | Bioprosthetic | |
|---|---|---|
| durability | lifelong | degenerates (faster in the young) → reintervention |
| anticoagulation | lifelong warfarin | none long term |
| favoured in | younger patients, already on warfarin | older patients, high bleeding risk, unreliable INR control, women planning pregnancy |
Age guide (aortic): mechanical <50, either 50–65, bioprosthetic >65 (ACC/AHA); ESC uses <60 and >65.
mechanical valves
Dabigatran (RE-ALIGN) and apixaban (PROACT-Xa) → more valve thrombosis than warfarin. Any position.
| Valve | INR target |
|---|---|
| aortic, modern bileaflet, no risk factors | 2.5 (2.0–3.0) |
| aortic + risk factor (AF, LV dysfunction, prior embolism, hypercoagulable) | 3.0 (2.5–3.5) |
| mitral or tricuspid | 3.0 (2.5–3.5) |
| On-X aortic valve (>3 months, no AF/extra stroke risk factor) | 1.5–2.0 + ASA (ACC/AHA 2b; Thrombosis Canada “may be candidates”; not endorsed by ESC 2025, which allows 2.0 [1.5–2.5] if high bleeding risk) |
- mitral valves are more thrombogenic (low-pressure inflow) → higher target
- add low-dose ASA only if another indication (e.g. CAD) and bleeding risk is low, or embolism despite therapeutic INR
- minor procedures (dental extraction, cataract, skin, device implant) → continue warfarin
- major surgery → stop warfarin before surgery and restart once bleeding risk allows (timing → periprocedural anticoagulation); bridge with LMWH/UFH for mechanical valves (Thrombosis Canada: all; ESC IIa: those with thromboembolic risk factors) — new-generation aortic valve without other risk factors → interruption without bridging may be considered (ESC IIb; ACC/AHA I for bileaflet AVR)
- bleeding → anticoagulant reversal
bioprosthetic valves
No other indication for anticoagulation:
- TAVI → ASA 81 mg alone — 12 months (ESC I), then lifelong (ESC IIa). No routine DAPT or anticoagulation; if OAC needed (e.g. AF) → OAC alone — POPular TAVI (2020): adding clopidogrel only added bleeding
- surgical bioprosthesis: aortic or mitral → warfarin (INR 2.5) for 3–6 months or ASA 81 mg; tricuspid/pulmonic → warfarin for 3 months or ASA (Thrombosis Canada). Afterwards lifelong low-dose ASA may be considered
With AF or another indication:
- anticoagulate as usual — DOAC acceptable (typically after the first 3 months for surgical valves)
- TAVI + AF → anticoagulant alone, no added antiplatelet
follow-up: compare with the baseline echo
- baseline TTE after implant (before discharge or within 1–3 months) → the reference for every later gradient. A gradient means little without it
- mechanical valve → INR monitoring and clinical review; repeat imaging only if symptoms or signs change
- bioprosthetic valve → routine TTE for degeneration. ESC: at 1 year, then yearly. ACC/AHA: surgical valves at 5 and 10 years, then yearly; TAVI yearly
- new symptoms, a new murmur or muffled mechanical clicks → TTE now. Suspected dysfunction with a normal TTE → TOE, gated CT or fluoroscopy anyway
prosthetic valve dysfunction: why is the gradient high?
New dyspnoea, heart failure, an embolic event or a rising gradient → work out the cause before treating the number. Obstruction ≈ mean gradient up >50% from baseline (aortic: >10 mmHg) once high flow is excluded (ACC/AHA). Don’t call stenosis on one number: pair a gradient or velocity with a less flow-dependent measure (EOA or DVI) (ASE). Symptomatic severe prosthetic stenosis → redo surgery, or valve-in-valve if surgical risk is high.
| Cause | Clues | Next step |
|---|---|---|
| valve thrombosis | mechanical valve with subtherapeutic INR or missed doses; sudden onset, embolism; restricted leaflet on fluoroscopy/TOE | → below |
| pannus | slow rise over years; INR has been therapeutic | contrast CT: pannus is late and high attenuation, thrombus early and low (they can coexist) → surgery if obstructive |
| structural degeneration (bioprosthesis) | gradual rise, years out; leaflet calcification or tear | valve centre → redo surgery or valve-in-valve TAVI |
| prosthesis–patient mismatch | gradient high from the first echo, not rising | rarely needs reoperation |
| high-flow state | anaemia, fever, sepsis, pregnancy | treat the cause, repeat echo |
| endocarditis | fever, bacteraemia, new regurgitation, new conduction block | cultures before antibiotics, TOE → infective endocarditis |
| paravalvular leak | regurgitation around the sewing ring; haemolysis (↑LDH, ↓haptoglobin, schistocytes) | intervene for symptoms or transfusion-requiring haemolysis (surgical or transcatheter closure) |
Acute pulmonary oedema or shock with a mechanical valve → assume thrombosis. Heparin now, emergency TOE plus fluoroscopy or CT for leaflet motion, and Heart Team. Emergency surgery (shock, large thrombus, possible pannus, recurrence, contraindication to lysis) or low-dose slow-infusion fibrinolysis (high surgical risk, right-sided valve). Non-obstructive thrombus → optimise anticoagulation, re-image; surgery if large (≥10 mm) with embolism.
Bioprosthetic valve thrombosis (rising gradient, thickened leaflets on TOE/CT; commonest in first 3 months, seen up to a few years out, commoner after TAVI):
- stable with raised gradient or confirmed thrombus → VKA first, then repeat imaging
- tends to recur → indefinite anticoagulation may be considered (ESC), weighed against bleeding
- incidental leaflet thickening on CT with normal gradients → significance uncertain, no routine treatment and no routine CT screening
endocarditis prophylaxis
Any prosthetic valve — including TAVI — prosthetic repair material, or prior IE → antibiotic prophylaxis for dental procedures manipulating the gingiva (extractions, oral surgery). Not for cleaning without gingival manipulation, GI/GU procedures or TOE → regimens in infective endocarditis.
pregnancy
Mechanical valves in pregnancy → high thrombotic risk, and warfarin is teratogenic → bioprosthesis preferred in women planning pregnancy; management → heart disease in pregnancy.
Prepared 2026-11-19. Not yet verified — check every number against the sources.